^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    5d
    A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Zheng Min
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    6d
    A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan)
    7d
    Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Jiataile (sacituzumab tirumotecan)
    7d
    Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan)
    9d
    KEYMAKER-U06 Substudy 06E: Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=298, Recruiting, Merck Sharp & Dohme LLC | N=228 --> 298
    Enrollment change
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • ifinatamab deruxtecan (DS-7300) • Jiataile (sacituzumab tirumotecan) • levoleucovorin calcium
    10d
    Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis. (PubMed, Lung Cancer)
    SacTMT, Chemo-Ami, and Chemo-IO-anti-VEGF offer superior efficacy over chemotherapy for EGFR-mutant NSCLC after TKI progression. SacTMT and Chemo-IO-anti-VEGF may have more favorable safety profiles than Chemo-Ami. This comparative evidence helps to inform clinical decision-making.
    Retrospective data • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Jiataile (sacituzumab tirumotecan)
    13d
    Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Jiataile (sacituzumab tirumotecan) • simmitinib (SYHA1817)
    14d
    Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan)
    14d
    Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Jiataile (sacituzumab tirumotecan) • limertinib (ASK120067)
    15d
    TroFuse-021: A Clinical Trial of Sacituzumab Tirumotecan in People With Ovarian Cancer (MK-2870-021) (clinicaltrials.gov)
    P3, N=900, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    19d
    Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University
    New P2 trial • Platinum resistant
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    28d
    TROP-2-Directed Antibody-Drug Conjugates in Advanced NSCLC: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Reconstructed Survival Outcomes. (PubMed, Crit Rev Oncol Hematol)
    TROP-2-directed ADCs demonstrate meaningful efficacy in previously treated advanced NSCLC, especially among EGFR-mutant and non-squamous histology patients, with survival and response outcomes superior to traditional chemotherapy. However, high rates of adverse events, particularly ILD, necessitate close monitoring. Further randomized and biomarker-driven studies are warranted to refine patient selection and optimize the therapeutic potential of these agents.
    Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)